Pramod Thomas is a senior correspondent with Asian Media Group since 2020, bringing 19 years of journalism experience across business, politics, sports, communities, and international relations. His career spans both traditional and digital media platforms, with eight years specifically focused on digital journalism. This blend of experience positions him well to navigate the evolving media landscape and deliver content across various formats. He has worked with national and international media organisations, giving him a broad perspective on global news trends and reporting standards.
RECORD tax raid from the HMRC on ultra-wealthy non-dom taxpayers has increased fears of wealth creators leaving the country due to rising costs, reported The Telegraph.
According to official data, non-doms and deemed domiciled individuals paid a staggering £12.4 billion in taxes during the financial year ending in 2022.
Despite a decrease in the number of people with non-dom status due to the pandemic, this marked a significant 10 per cent increase compared to the previous year and represents the highest amount recorded since data collection began in 2008.
Despite a decline in the number of non-doms compared to pre-pandemic years, the tax revenue increased. This is attributed to changes in rules implemented in 2017, which have resulted in a growing number of wealthy internationals losing their tax benefits, The Telegraph report added.
The non-dom individuals are those who are UK residents but have a permanent home outside the country. They pay British taxes only on income earned in the country for the first seven years, but not on foreign income. After this point, they pay an annual fee to benefit from this remittance, starting at £30,000 and rises to £60,000.
The change in rule introduced in 2017, impacts non-domiciled individuals residing in the UK. Under the new rule, if a non-dom has been a UK resident for 15 out of the 20 years preceding their tax return year, their tax status is transformed into deemed domicile.
As a result, they are obligated to pay taxes in the UK at the applicable rates on their global income. This change exposes them to significant potential increases in their tax liabilities.
Opposition Labour already announced plans to scrap the non-dom system following the media storm surrounding prime minister Rishi Sunak’s wife, Akshata Murty.
Last year, it emerged that Murty had non-dom status. She later said she would start paying UK tax on her overseas earnings as she did not want to be a 'distraction' for her husband.
According to Lucy Woodward, a partner in the private wealth team at Saffery Champness, the shift to becoming deemed domiciled has already pushed some wealthy internationals to leave the country.
She revealed that one of her clients has express intention to leave the UK if the non-dom system is scrapped.
“It is also the public opinion against non-doms and that sense feeling unwelcome," she is reported to have said.
Chris Etherington, private client partner at RSM accountants, views the 2017 measures as 'an attack on non-doms'.
“The biggest concern among a lot of our clients is around what Labour’s proposals are in abolishing the non-dom status altogether. I think individuals who are globally mobile will take action if the domicile status was taken away," Etherington was quoted as saying by The Telegraph.
In the tax year following 2022, individuals categorised as deemed domiciled will also experience the impact of the chancellor's discreet tax increase on both incomes and inheritances.
Higher-income earners are expected to bear a disproportionate burden due to the freezing of tax thresholds, as a larger portion of their income falls within the highest tax bracket, the report added.
UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.
Investment gap
Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.
Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.
Richard Torbett, ABPI Chief Executive, noted “The UK can lead globally in medicines and vaccines, unlocking billions in R&D investment and improving patient access but only if barriers are removed and innovation rewarded.”
The UK invests just 9% of healthcare spending in medicines, compared with 17% in Spain, and only 37% of new medicines are made fully available for their licensed indications, compared to 90% in Germany.
Expert reviews
Shailesh Solanki, executive editor of Pharmacy Business, pointed that “The government’s own review shows the sector is underfunded by about £2 billion per year. To make transformation a reality, this gap must be closed with clear plans for investment in people, premises and technology.”
The National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold £20,000 to £30,000 per Quality-Adjusted Life Year (QALY) — has remained unchanged for over two decades, delaying or deterring new medicine launches. Raising it is viewed as vital to attracting foreign investment, expanding patient access, and maintaining the UK’s global standing in life sciences.
Guy Oliver, General Manager for Bristol Myers Squibb UK and Ireland, noted that " the current VPAG rate is leaving UK patients behind other countries, forcing cuts to NHS partnerships, clinical trials, and workforce despite government growth ambitions".
Reeves’ push for reform, supported by the ABPI’s Competitiveness Framework, underlines Britain’s intent to stay a leading hub for pharmaceutical innovation while ensuring NHS patients will gain faster access to new treatments.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.